News | April 05, 2021
Tatva Chintan Pharma Chem plans for IPO files DRHP with SEBI
TCPCL is the largest and only commercial manufacturer of SDAs for zeolites in India
TCPCL is the largest and only commercial manufacturer of SDAs for zeolites in India
Report outlines the wide array of investment opportunities in various segments of India’s healthcare sector
Integration of various regulatory agencies with a single-window system and putting in place a transparent, stable, predictable and easy to navigate interface.
NPPA also fixed retail price of 76 new drugs in the meeting dated 10th March 2021 to be launched by existing manufacturers including off-patent Anti-diabetic drugs allowing due benefit of patent expiry to the patients.
The company will add a single-use assembly production unit at its Life Science Center in Molsheim, France.
The vaccine was 85 percent effective in preventing severe disease across all regions.
Besides powering the drug discovery efforts, phytopharmaceuticals have a huge potential to create a niche market for itself, thereby helping to expand the bio-economy.
The next phase of growth in pharma depends on the industry-oriented workforce, risk investment, academic revamp, and creation of R&D hubs, say experts .
Bharat Biotech expects to share further details of the trial results as additional data become available.
The Govt. launched the PLI scheme for bulk drugs with a financial outlay of Rs 6,940 crores across 53 APIs over 6 years.
Subscribe To Our Newsletter & Stay Updated
